Most Recent
Swiss pharmaceutical company Actelion has brought a fourth patent infringement case over plans to launch a generic version of its blood pressure drug in Australia -- against Lupin unit Generic Health -- after firing off cases against three other drug makers.
Cipla Australia wants an undertaking it intends to give pharma company Actelion over plans to launch a generic version of a blood pressure drug to be shielded from rivals Arrotex, Nova Pharmaceuticals and MSN Laboratories, as those companies battle patent infringement claims.
Swiss drug companies Actelion and J&J's Janssen-Cilag have brought litigation against three generics makers over their plans to launch cheaper versions of two blood pressure medications.
A judge has rejected ride-on toy maker Smart Trike's bid to withdraw admissions in a dispute with Target due to errors by its lawyers, saying the company had failed to adequately explain how the admissions came to be made and repeated in three versions of its defence.
Children's ride-on toys manufacturer Smart Trike wants to withdraw admissions it made in a dispute with Target over a convertible stroller recall, blaming its lawyers for what it says was an error.
A judge has refused to bifurcate a dispute between Smart Trikes and Target over the supply and eventual recall of allegedly unsafe convertible strollers, finding any time and cost savings were likely to prove illusory.
Sandoz has accused Amgen of 'dragging the chain' as the Swiss biotech continues to mull whether to launch infringement proceedings over six patents for its Prolia and Xgeve bone disease biologics.
Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen's bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.
Despite failing a second time to make the deadline, Advanta Seeds has won an extension to pay a renewal fee for its patent for a lucrative hybrid canola plant cell.
Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.